| scholarly article | Q13442814 |
| P50 | author | Juan Carlos Izpisúa Belmonte | Q6299291 |
| Núria Montserrat | Q41679242 | ||
| Ignacio Sancho-Martinez | Q42182266 | ||
| Guang-Hui Liu | Q86848874 | ||
| Emmanuel Nivet | Q125309424 | ||
| Rupa Devi Soligalla | Q125309560 | ||
| April Goebl | Q125309567 | ||
| Ilir Dubova | Q125309617 | ||
| P2093 | author name string | James Thompson | |
| Mo Li | |||
| John Yates | |||
| Bing Ren | |||
| Ying Li | |||
| Fei Yi | |||
| Jessica Kim | |||
| Jing Qu | |||
| Weiqi Zhang | |||
| Sergio Ruiz | |||
| Ulrich Wagner | |||
| Concepcion Rodriguez Esteban | |||
| Keiichiro Suzuki | |||
| Xiuling Xu | |||
| Audrey Kim | |||
| P2860 | cites work | Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression | Q24293587 |
| Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice | Q24317631 | ||
| 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
| Lamin A-dependent nuclear defects in human aging | Q24681309 | ||
| Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? | Q27026262 | ||
| Lamin B1 duplications cause autosomal dominant leukodystrophy | Q28261772 | ||
| Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death | Q28568204 | ||
| Diseases of the nuclear envelope | Q33687043 | ||
| Parkinson's disease: insights from pathways | Q33871291 | ||
| Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex | Q33928452 | ||
| Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
| Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress | Q34604521 | ||
| Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin | Q34766646 | ||
| Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome | Q34930935 | ||
| Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors | Q35002960 | ||
| Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice | Q35134204 | ||
| Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons | Q35579834 | ||
| Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors | Q35749996 | ||
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
| Clinical and pathological characteristics of LRRK2 G2019S patients with PD. | Q35911042 | ||
| Lower cognitive performance in healthy G2019S LRRK2 mutation carriers | Q36198611 | ||
| The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease | Q36325701 | ||
| Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs | Q36345932 | ||
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
| Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. | Q36798321 | ||
| Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors | Q36893512 | ||
| Diseases in a dish: modeling human genetic disorders using induced pluripotent cells | Q37965334 | ||
| Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. | Q39681242 | ||
| Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease | Q42962537 | ||
| Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs | Q43180292 | ||
| A mutation in VAPB that causes amyotrophic lateral sclerosis also causes a nuclear envelope defect | Q83756955 | ||
| P433 | issue | 7425 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neural stem cell | Q2944097 |
| P304 | page(s) | 603-7 | |
| P577 | publication date | 2012-11-22 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 | |
| P478 | volume | 491 |
| Q64785438 | 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing |
| Q90182303 | A Single "All-in-One" Helper-Dependent Adenovirus to Deliver Donor DNA and CRISPR/Cas9 for Efficient Homology-Directed Repair |
| Q92593882 | A compendious summary of Parkinson's disease patient-derived iPSCs in the first decade |
| Q35661159 | A computational approach to detect and segment cytoplasm in muscle fiber images |
| Q37596293 | A cut above the rest: targeted genome editing technologies in human pluripotent stem cells |
| Q33931201 | A novel suppressive effect of alcohol dehydrogenase 5 in neuronal differentiation |
| Q38697548 | A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway |
| Q35563718 | A widely adaptable approach to generate integration-free iPSCs from non-invasively acquired human somatic cells |
| Q35635245 | Advances in reprogramming-based study of neurologic disorders |
| Q35827841 | Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging |
| Q38642565 | Back and forth in time: Directing age in iPSC-derived lineages. |
| Q92776336 | Basic and translational aging research in China: present and future |
| Q41631240 | Beating in a dish: new hopes for cardiomyocyte regeneration |
| Q92344989 | Bi-allelic Homology-Directed Repair with Helper-Dependent Adenoviruses |
| Q89397415 | CRISPR/Cas9-mediated gene knockout reveals a guardian role of NF-κB/RelA in maintaining the homeostasis of human vascular cells |
| Q33628110 | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. |
| Q47933224 | Calpain-Dependent Degradation of Nucleoporins Contributes to Motor Neuron Death in a Mouse Model of Chronic Excitotoxicity. |
| Q35171879 | Clinical therapy using iPSCs: hopes and challenges |
| Q27004350 | Concise review: Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversion |
| Q30653185 | Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration |
| Q37554021 | Current Opinion on the Role of Neurogenesis in the Therapeutic Strategies for Alzheimer Disease, Parkinson Disease, and Ischemic Stroke; Considering Neuronal Voiding Function. |
| Q36923003 | DNA methylome: Unveiling your biological age |
| Q40232826 | Developmental SALL2 transcription factor: a new player in cancer |
| Q93041128 | Direct Reprogramming to Human Induced Neuronal Progenitors from Fibroblasts of Familial and Sporadic Parkinson's Disease Patients |
| Q42427157 | Direct reprogramming of porcine fibroblasts to neural progenitor cells |
| Q38107799 | Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells |
| Q35816077 | Eliminate mitochondrial diseases by gene editing in germ-line cells and embryos |
| Q42132563 | Fas-Activated Mitochondrial Apoptosis Culls Stalled Embryonic Stem Cells to Promote Differentiation |
| Q47230590 | First stem cell transplantation to regenerate human lung |
| Q27692698 | From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease |
| Q38788754 | From the first human gene-editing to the birth of three-parent baby |
| Q90263856 | G2019S Variation in LRRK2: An Ideal Model for the Study of Parkinson's Disease? |
| Q37480373 | Gain-of-function mutations in the ALS8 causative gene VAPB have detrimental effects on neurons and muscles |
| Q42149489 | Gene Editing with Helper-Dependent Adenovirus Can Efficiently Introduce Multiple Changes Simultaneously over a Large Genomic Region |
| Q64785221 | Generating Neural Stem Cells from iPSCs with Dopaminergic Neurons Reporter Gene |
| Q54972398 | Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease. |
| Q94465937 | Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells |
| Q38113338 | Genome editing of human pluripotent stem cells to generate human cellular disease models |
| Q38842828 | Genome engineering tools for building cellular models of disease |
| Q30573111 | Global DNA methylation and transcriptional analyses of human ESC-derived cardiomyocytes |
| Q34497765 | Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication |
| Q34100703 | Hippocampal proliferation is increased in presymptomatic Parkinson's disease and due to microglia |
| Q37393979 | Homology Requirements for Efficient, Footprintless Gene Editing at the CFTR Locus in Human iPSCs with Helper-dependent Adenoviral Vectors |
| Q41868474 | Human iPSC-based modeling of late-onset disease via progerin-induced aging |
| Q38428477 | Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery. |
| Q38168763 | Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development |
| Q38865951 | I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway |
| Q57454780 | Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development |
| Q39040578 | Induced pluripotent stem cell technology: a decade of progress |
| Q64785219 | Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease |
| Q26771402 | Induced pluripotent stem cells for modeling neurological disorders |
| Q41903542 | Inducing cellular aging: enabling neurodegeneration-in-a-dish |
| Q38368574 | Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond |
| Q37542688 | Integrating Gene Correction in the Reprogramming and Transdifferentiation Processes: A One-Step Strategy to Overcome Stem Cell-Based Gene Therapy Limitations |
| Q34431170 | Investigating human disease using stem cell models |
| Q90672879 | Investigating pediatric disorders with induced pluripotent stem cells |
| Q37368913 | LRRK2 Inhibits FAK Activity by Promoting FERM-mediated Autoinhibition of FAK and Recruiting the Tyrosine Phosphatase, SHP-2 |
| Q28078899 | LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives |
| Q36888947 | LRRK2: an éminence grise of Wnt-mediated neurogenesis? |
| Q36125111 | Large-scale generation of human iPSC-derived neural stem cells/early neural progenitor cells and their neuronal differentiation |
| Q38738931 | Linking adult hippocampal neurogenesis with human physiology and disease |
| Q36800354 | Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons. |
| Q50140931 | Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells |
| Q33850635 | Mechanisms and consequences of aneuploidy and chromosome instability in the aging brain |
| Q48239635 | Mechanisms of Mutant LRRK2 Neurodegeneration |
| Q38852795 | Metabolic rescue in pluripotent cells from patients with mtDNA disease |
| Q38666481 | Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells |
| Q38783743 | Modeling Axonal Defects in Hereditary Spastic Paraplegia with Human Pluripotent Stem Cells |
| Q64264903 | Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells |
| Q52431644 | Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. |
| Q91637510 | Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells |
| Q35056065 | Modeling human neurological disorders with induced pluripotent stem cells |
| Q47566317 | Modeling neurological diseases using iPSC-derived neural cells : iPSC modeling of neurological diseases |
| Q38238081 | Modeling physiological and pathological human neurogenesis in the dish |
| Q35923231 | Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs |
| Q34918292 | Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs |
| Q57288794 | Multiplication of the SNCA locus exacerbates neuronal nuclear aging |
| Q40260539 | Multisystem Lewy body disease and the other parkinsonian disorders |
| Q24318474 | Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies |
| Q45719229 | Myopathy in Marinesco-Sjögren syndrome links endoplasmic reticulum chaperone dysfunction to nuclear envelope pathology |
| Q64057548 | Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality |
| Q38268886 | Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression |
| Q85420882 | Neurodegenerative disease: neural stem cell degeneration in PD linked to nuclear defects |
| Q38065693 | New march towards the regeneration of sensation and cognition: hear more, see more and learn more |
| Q28080682 | Non-coding RNA in neural function, disease, and aging |
| Q37199039 | Olfactory stem cells reveal MOCOS as a new player in autism spectrum disorders |
| Q64223489 | One Step Into the Future: New iPSC Tools to Advance Research in Parkinson’s Disease and Neurological Disorders |
| Q38093796 | Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases |
| Q63246542 | Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
| Q34353458 | Opportunities and challenges of pluripotent stem cell neurodegenerative disease models |
| Q38085689 | Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. |
| Q36446405 | PINK1 expression increases during brain development and stem cell differentiation, and affects the development of GFAP-positive astrocytes |
| Q36392356 | PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype |
| Q48192270 | Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation |
| Q89786852 | Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging |
| Q54406203 | Pathogenic LRRK2 mutations in nuclear ageing--a new organelle to study in Parkinson's disease. |
| Q47165819 | Personalized medicine in a dish: the growing possibility of neuropsychiatric disease drug discovery tailored to patient genetic variants using stem cells |
| Q42263195 | Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. |
| Q51068766 | Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. |
| Q43237748 | Positioning nuclei within the cytoplasm of striated muscle fiber: cooperation between microtubules and KASH proteins |
| Q35761135 | Probing disorders of the nervous system using reprogramming approaches |
| Q42545361 | Proceedings: cell therapies for Parkinson's disease from discovery to clinic |
| Q64109854 | Production of CRISPR/Cas9-Mediated Self-Cleaving Helper-Dependent Adenoviruses |
| Q27008903 | Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency |
| Q36907411 | Progress and prospects in stem cell therapy |
| Q28394874 | Reevaluation of the safety of induced pluripotent stem cells: a call from somatic mosaicism |
| Q38759026 | Regenerative strategies for kidney engineering |
| Q91628294 | Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction |
| Q37641537 | Role of Jnk1 in development of neural precursors revealed by iPSC modeling |
| Q40349749 | SIRT2 regulates nuclear envelope reassembly through ANKLE2 deacetylation |
| Q59087455 | SIRT6 deficiency results in developmental retardation in cynomolgus monkeys |
| Q36559986 | SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. |
| Q34094995 | Scientific progress regarding neural regeneration in the Web of Science: A 10-year bibliometric analysis |
| Q27324311 | Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes |
| Q55383139 | Sequential Application of Discrete Topographical Patterns Enhances Derivation of Functional Mesencephalic Dopaminergic Neurons from Human Induced Pluripotent Stem Cells. |
| Q38989390 | Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. |
| Q33358637 | Solving the puzzle of Parkinson's disease using induced pluripotent stem cells |
| Q38973220 | Spatial genome organization and cognition |
| Q34845881 | Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells |
| Q61799889 | Stress-induced precocious aging in PD-patient iPSC-derived NSCs may underlie the pathophysiology of Parkinson's disease |
| Q58762401 | Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models |
| Q34088395 | Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. |
| Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
| Q38160939 | Targeting leucine-rich repeat kinase 2 in Parkinson's disease |
| Q26765894 | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease |
| Q38722713 | The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders |
| Q99585801 | The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations |
| Q37666286 | The translational potential of human induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology |
| Q28833688 | Toward pluripotency by reprogramming: mechanisms and application |
| Q38257305 | Transcriptional comparison of human induced and primary midbrain dopaminergic neurons |
| Q39085008 | Understanding Parkinson's Disease through the Use of Cell Reprogramming |
| Q41265657 | Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells |
| Q57026122 | Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes |
| Q26799590 | Using iPS Cells toward the Understanding of Parkinson's Disease |
| Q90733806 | Using induced pluripotent stem cells for modeling Parkinson's disease |
| Q30844698 | Visualization of aging-associated chromatin alterations with an engineered TALE system |
| Q37059940 | Vitamin C alleviates aging defects in a stem cell model for Werner syndrome |
| Q42347521 | What if it was easier to prevent schizophrenia than to treat it? |
| Q26782120 | When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease |
| Q41821215 | Why Quantification Matters: Characterization of Phenotypes at the Drosophila Larval Neuromuscular Junction |
| Q46579323 | iPS cells in the study of PD molecular pathogenesis |
| Q46043945 | iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases |
Search more.